The Manufacturers Life Insurance Company Purchases New Position in Bristol Myers Squibb Company $BMY

The Manufacturers Life Insurance Company bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,176,661 shares of the biopharmaceutical company’s stock, valued at approximately $125,419,000. The Manufacturers Life Insurance Company owned 0.11% of Bristol Myers Squibb at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $27,000. Finally, Bayban acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter worth $31,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Truist Financial reiterated a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Roth Capital began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 target price on the stock. Finally, Piper Sandler began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $67.86 on Wednesday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The stock’s 50-day moving average price is $61.01 and its 200-day moving average price is $59.54. The stock has a market capitalization of $138.62 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.